Type 2 Diabetes Type 2 Diabetes
Conditions
Interventions
Subjects assigned to the SMC-01 group will use the SMC-01 in conjunction with self-management between visits. In contrast, subjects assigned to the control group practice normal self-management. In bo
Sponsors
Ohnishi Yukiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Outpatients who are 20 years of age or older at the time of obtaining consent (regardless of gender) 2) Patients who have written consent at the time of Visit 1 3) Patients who, at Visit 1, have been diagnosed with type 2 diabetes for at least 12 weeks (84 days) 4) Patients being treated with diet and exercise therapy alone or taking hypoglycemic medications in addition to diet and exercise therapy, who have been on the same therapy for at least 12 weeks (84 days) at the time of Visit 1. 5) Patients with a Visit 1 HbA1c value of 7.0% to 9.0% or less 6) Patients who have a smartphone device and have been using it continuously for at least 12 weeks (84 days) at the time of Visit 1. 7) Patients who have been confirmed by the investigator as having no problems with the input eligibility of the test device.
Exclusion criteria
Exclusion criteria: 1) Women who wish to become pregnant, are pregnant, or are breastfeeding. 2) Premenopausal women with a positive pregnancy test (urine) 3) Patients who have been diagnosed with type 1 diabetes 4) Patients who have been diagnosed with secondary diabetes mellitus 5) Patients who received insulin within 12 weeks (84 days) retroactive to Visit 1 6) Patients with a history of requiring third party intervention for the treatment of hypoglycemia 7) Patients with or undergoing treatment for diabetic proliferative retinopathy 8) Patients who developed cardiovascular disease within 12 weeks (84 days) retroactive to Visit 1 9) Patients with noncompensated heart failure 10) Patients with serious hepatic impairment (ALT value (central bulk measurement at Visit 1) greater than 3 times the upper limit of the reference value) 11) Patients with renal impairment (eGFR less than 45 mL/min/1.73m2 or urinary micro albumin of 300 mg/gCre or more (both values from the central batch measurement at Visit 1). 12) Patients with chronic diseases requiring continuous use (internal, injection, inhalation) of corticosteroids, immunosuppressive agents, loop diuretics, etc. 13) Patients with a malignant tumor (recurrence-free period less than 5 years) or infection (sepsis) 14) Patients who are scheduled to be hospitalized or undergo surgical procedures during the study period 15) Patients with drug addiction, alcoholism, or unstable psychiatric illness 16) Patients with non-diabetic disease for whom exercise restriction is indicated 17) Patients whose HbA1c levels measured within 4-10 weeks prior to Visit 1 (in-hospital measurements) and the variability of HbA1c levels at Visit 1 (in-hospital measurements) is greater than +/-1.0%. 18) Patients who have participated, are currently participating, or will participate during the course of this study, in a clinical trial or post-marketing clinical trial for another prescription drug or medical device within 12 weeks (84 days) retroactive to Visit 1. 19) Patients who, within 12 weeks (84 days) prior to Visit 1, have used a mobile application running on a smartphone device for the purpose of managing or assisting in the management of diabetes or performing an autologous blood glucose measurement, and the investigator determines that the impact of such use on the evaluation of the efficacy of the study cannot be ruled out. 20) Patients planning to replace their smartphone device within 24 weeks of Visit 2 21) Medical institution staff or close relatives involved in the study 22) Employees of Save Medical, Inc. or employees of companies entrusted with work related to this clinical trial 23) Patients who are unable to comply with or do not agree to any of the rules for hospital visits and medication adherence specified in this study. 24) Other patients deemed by the investigator to be inappropriate for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HbA1c from baseline at the end of the treatment period | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c Fasting Blood Glucose Fasting Insulin Fasting Intact Proinsulin to Insulin Ratio Self Management Adherence Rate | — |
Contacts
Public ContactSatoshi Nozoe
Save Medical Corporation
Outcome results
None listed